|
|
Post by mindovermatter on Nov 10, 2015 10:55:53 GMT -5
In this battle with the Shorts I'm also not sure that this matters. If only $100m , and sales dont pick up, then MNKD issues some more stock (again I'm fine with that). Regardless $100m or $150M we now have up to 50M shares in hands of people who act like Longs, who see value in MNKD if the share price goes up. I think that is the more significant number here: 50M shares that cant be shorted and have value if they go up. Chaotic systems are all about initial conditions and equilibrium. I cant but help feel that a butterfly has started flapping its wings against the shorts. Yes these are difficult times for MNKD. But listing on TASE may yet turn out to be a masterstroke. And if it does, I hope there will be a lot of soul searching at Nasdaq, SEC. What would it say about the US being the pre-eminent market for capital creation.? In the future would all biotechs start listing in TASE instead? One other thing I was curious about .... hear me out: Here's a quote from Matt from yesterday's call: "We expect that the majority of shares for index fund purchases will be issued directly for MannKind, with remaining demand required to be satisfied by open market purchasers from existing holders to fulfill these ownership requirements. All purchases are expected to be completed within the next week." -- SourceSounds to me like 50M shares might not cut it! ETFs balance on a overall % of their funds, not on a total # of shares basis. Therefore, there are two ways to look at what might happen: In the filing, MNKD says expected amount is up to ~$140M. Now, 50M shares at $2/share is less than at $3/share. At the $2/share, if the ETFs have a percentage holding goal for MNKD (which I'm sure they do), they'll need to buy more than the 50M shares to satisfy the same % holding. So, from the shorts' perspective, knocking down our price is good in that we'll get less capital from the offering, but it's also potentially bad as more than 50,000,000 shares might be gobbled up by the ETFs, and since they're long-term holders and cannot lend them, that'd mean less available shares to short for the shorts. Thoughts?
Taken from: mnkd.proboards.com/thread/4014/resolved-debt?page=3#ixzz3r6WNLBvbWhen you pull something like this from a position of weakness as Mannkind is right now, this is what happens. It might have been better for Al to gift the money to Mannkind instead of doing this. But even he isn't that stupid. |
|
|
|
Post by mindovermatter on Nov 10, 2015 10:31:19 GMT -5
Perfect time to take the company private when the share price is so beat down. You just never know what is around the corner. You do realize if he does this, he'll screw over the vast majority of his retail investors which means the vast majority of people on this board who defend him regardless of what he does? Al taking the company private here would be the ultimate stab in the back to retail investors. E tu Al? |
|
|
|
Post by mindovermatter on Nov 10, 2015 10:29:58 GMT -5
I have been thinking about that exact same thing....Just rookie like .....reaffirms the credibility of this management team.......strange Plead? How do you get that interpretation from Hakan's comment:
"As I mentioned last quarter, we were pleased to welcome the new Chief Medical Officer leading the development team. And in the last couple of months, our development group has been very busy moving ahead with the formulation work on the pulmonary hypertension program, as well as lining up a dozen more product candidates with commercial potential. And there is no way we can fund all of this potential activity, so we have also initiated discussions with several firms that could participate in product development as strategic or financial partners.
"I have made it clear that I'm open to any creative approach that will give us as many of these programs as possibly funded, and get our technology into the hands of healthcare providers and their patients. So to the participants listening to this call, who have an interest in sharing the risk and the rewards of our product development effort or who have a formulation or drug delivery challenge that our technology may address, I would say this, let's talk. My ambition is to have a robust portfolio of product candidates in the pipeline by this time next year."
---
It amazes me how the same shareholders who complain that Hakan is not using his leadership role, to promote MannKind, then turn around and criticize when he does.
"...let's talk" is an invitation. Hakan did exactly the right thing, and I hope that Hakan will soon start bringing Dr. Urbanski to speak at these conferences.
---
Finally, the silence speaks VOLUMES here... where is mention of the pain med? I'm very confident at this point that we have a partner for a TS pain API and Hakan is restrained from even mentioning it by a confidentiality agreement. The pain pipeline is too big for Hakan to have ignored it like this. I'm speculating about a new partner, of course, but I'm going to put my money on it and start loading up. What did Hakan say about this? Here's his response to Jay Olson:
Jay Olson
"Okay. And then, just on the pipeline, I appreciate the color there on the progress; can you tell us how close you are to moving any of your pipeline assets into the clinic, and when is the soonest that MannKind could sign a partnership or licensing deal to monetize some of those pipeline assets?"
Hakan Edstrom
"Well, in regards to -- I would say they are certainly month away from going into a clinic. I mean, they are in the formulation stage right now, particularly on the pulmonary hypertension. In regards to entering into other development partnership or financial partnership, the only thing I can say that, that actioned [ph] over the last week, we've had discussions with potential partners. However, there are still negotiations to be had. So I would say -- I would hope that we could possibly announce something before the end of the year -- oh, sorry, within the next quarter, but that's as specific as I can be at this point in time."
---
'nuff said.
Two things. 1) Did Mannkind not mention that they'd have one TS candidate announce by the EOY about 6 months ago or am I mistaken on ? 2) While I haven't personally said anything about Hakan and his ability to promote, you don't find it quite odd he did so during a quarterly conference call? And that didn't struck you as odd if not almost borderline desperate? I have heard plenty of calls and never have I heard a CEO do that. I just don't think that was the place to do so. Hopefully he'll get some calls. |
|
|
|
Post by mindovermatter on Nov 10, 2015 10:24:52 GMT -5
Why is Al so silent? I would have thought he would be on a tour of the country promoting Afrezza's FDA approval & how big of an impact this will have on the diabetic community. Aside from the obvious (long investors) the losers will be the millions of diabetics who will continue to suffer. Sad state of affairs for a revolutionary product! I don't believe Al is in good health and is limiting his travels. |
|
|
|
Post by mindovermatter on Nov 10, 2015 10:08:37 GMT -5
-----
Am I interpreting this correctly? Did Matt just tell shareholders that MannKind Corporation does not want to allow those who have shorted MNKD to have a painless way out?
If so, then it makes me wonder if Al (or management) is planning to inflict some pain of their own against short interests.  
If Al dislikes the shorts, why is this move happening now of all times? Why didn't happen earlier this year? Or last year? or the year before? Or the year before that? And why did Al negotiate a deal with BofA to lend them 9 million shares knowing BofA could lend them out to short? The silly notion that Al is going to take care of the shorts hasn't happened and never will. What will is when Mannkind finally sees skyrocketing Afrezza sales or if Mannkind gets bought out at a nice premium. And I don't believe listing on the TASE is going to do anything to hurt the shorts. It will be business as usual. Maybe it's time for Mannkind to actually execute. |
|
|
|
Post by mindovermatter on Nov 10, 2015 9:49:16 GMT -5
No, this post is about helping Mannkind to have the best chance of survival. Think about giving Mannkind the best chance to survive NOT fighting among ourselves or accusing other investors of their investing philosophy. Personally, I have never loan my shares out. --- Give Mannkind the best opportunity to execute --- It's just an idea that may change to course of Mannkind future. I forgot the third and fourth way. Lend Mannkind $100,000,000. Or get someone to buy out the company. |
|
|
|
Post by mindovermatter on Nov 10, 2015 9:47:26 GMT -5
According to the MNKD SEC filing:
"Pursuant to the stock purchase agreements, the shares of common stock will be sold at a price per share equal to 97% of the closing price of the Company's common stock on the TASE on November 12, 2015, which is the trading day immediately preceding the first day on which the Company's common stock will enter specified TASE stock indexes."
So, for the next two trading days:
--- If you have any dry powder, PURCHASE more MNKD shares even token amount. --- If you are currently loaning out shares for shorts, recall them back so that shorts can't use them to drive the share price down. You can resume loaning out again after November 12.
Will this idea help Mannkind to have the best chance to survive for Afrezza to establish a foothold in the market? Sorry, but you can buy all you want and not lend out your shares but that's not going to save Mannkind. It's like thinking by buying an electric car that you are saving the environment. It's not that simple but sure sounds good and makes you feel better. The way Mannkind survives is two fold. Afrezza needs to take off and start selling in quantity to start making a profit and Mannkind needs to show that Technosphere isn't a one trick pony. So far Mannkind has not done a very good job in executing on the next Technosphere candidate. I might be mistaken but two conference calls ago (or maybe it was at an investors conference) it was intimated that another TS candidate was soon to be released. To date, we still have no idea what is going on. My only guess is that Mannkind thought they had a deal but that blew up and the partner walked away. If I remember correctly, the "every 6 month for a TS candidate" pushed by Matt in the beginning part of the year hasn't yet come to fruition. I understand things don't always go as planned but Mannkind no longer has the luxury of missed business opportunities now. Mannkind will only survive if it can actually execute its business plan and so far its not going anywhere as well as they had hoped. |
|
|
|
Post by mindovermatter on Nov 10, 2015 9:15:50 GMT -5
Ok, folks. This is what it comes down to and it's not like we should fein surprise at where the company is today. Anyone following our story and doing reasonable due diligence should know that the company needs to raise capital. It's not rocket science. The news has been out there for at least two financial quarters. It's time to man up now. Blame is for losers. Winners work harder. It's easy to complain when times are difficult. I'm adding to my position. I like the odds. I like the potential return on this $2+ stock. We have another year, for sure. And, after that, who knows. But that's what you get in life. Some folks don't even get that. Isn't this National Cancer Awareness month? Yes, there are problems. But blaming management is short sided. You have not walked a mile in their shoes. You have no idea. You don't. You know a lot less then you think you do, at least about this management team. You want to get out, then get out. And then go away. I'm staying. More. I'm adding shares. If you can't add, then hold. And do it with some inner strength. Anyone who follows what I write knows that I write about potential and nothing has changed in the light of yesterday's news or today's news regarding MannKind, Technosphere, or Afrezza. In reality, we may never have ever had more than a year or two without financing issues with which to contend in the multi years I have been invested here. Al Mann will NOT allow MannKind to sink for want of capital to see the company through this difficult time, not with all that Al has already invested in ten years of development and a billion dollars of his own money. And, not with another billion in his portfolio. MannKind will be successful. Afrezza will be successful. Stop your sniveling. You've been given two victories this week. Sanofi reaffirmed and MannKind refinanced. Respect. Rob, What are your thoughts when Hakan said this: "I have made it clear that I'm open to any creative approach that will give us as many of these programs as possibly funded, and get our technology into the hands of healthcare providers and their patients. So to the participants listening to this call, who have an interest in sharing the risk and the rewards of our product development effort or who have a formulation or drug delivery challenge that our technology may address, I would say this, let's talk. My ambition is to have a robust portfolio of product candidates in the pipeline by this time next year." I thought it was quite odd as I have never heard a CEO during a quarterly conference call give a sales pitch. |
|
|
|
Post by mindovermatter on Nov 9, 2015 23:12:09 GMT -5
This is as far as she can legally go in promoting it. Maybe if she did it topless we'd see prescriptions rise exponentially. My wife dared me to type this thinking I'd be too chicken to post it. Boy did I prove her wrong! |
|
|
|
Post by mindovermatter on Nov 9, 2015 21:30:56 GMT -5
Has anyone ever heard a CEO on a conference call plead for other companies to partner with them? That was a first for me and it really was awkward listening to Hakan do that.
|
|
|
|
Post by mindovermatter on Nov 9, 2015 21:21:45 GMT -5
And tomorrow we'll see if this was priced in and part of the recent slide or if there's more sliding to come. I'm already in deep but am moving some things around to make room. I'm going to consciously violate my "no single stock of more than 10% of net worth rule" if this thing goes on sale much deeper. Too bad we didn't plan ahead and dilute when we were trading at 7 or so. AH trading would suggest that it wasn't priced in. The bottom has yet to be seen imo. Management didn't do its investors any favors today. Sorry to be negative but there are some things you just can't spin and today's quarterly call was like listening to someone singing off key in front of a lot of people. |
|
|
|
Post by mindovermatter on Nov 9, 2015 21:13:47 GMT -5
The index funds don't allow shares to be shorted but how do they police this and who over sees that they aren't? I am bringing this up because it's no secret that financial entities don't always do as they say and follow the rules when making money is involved.
|
|
|
|
Post by mindovermatter on Nov 9, 2015 20:30:20 GMT -5
Mind: Mahalo for the kind welcome. Things fell apart for me on the other board and I closed my account there. I have not bird-dogged my script yet for Afrezza. Why? Cuz I'm waiting for it to get easier to obtain! It's that simple. I'm not going thru with all the hassle/roadblocks to get it. My control is excellent so I can wait. Once things get easier, and I don't have educate my doctor on what Afrezza is, (she had never heard of it), I will go on it. Sorry to hear that but IHUB is like the wild west. This is a much more civilized board. Hopefully the script process will get easier by the early part of 2016. |
|
|
|
Post by mindovermatter on Nov 9, 2015 20:24:08 GMT -5
You are right to give kudos to the interviewer as she tries to coax something positive from Sanofi's rep in the interview, but it's like pulling teeth. I've watched several of these interviews from different cities(same sanofi rep)and the one commonality is that she(Sanofi's rep) goes out of her way to downplay Afrezza. She has obviously been coached to downplay the drug's positive points. On several occasions, the interviewer will try to get her to say anything positive about Afrezza, but the response is always the same-it's another option and talk to your doc to see if this is right for you. She always remarks that children can't use the drug, but never mentions that current pediatric trials are underway. I'm not a conspiracy theorist but either she is purposely downplaying this drug, or Sanofi just doesn't think much of it. I'm beginning to think that the former might be true, for whatever reason. It's done on purpose only because she can't make the claims that people using it are experiencing. And like a commercial, she has to give the disclaimers. But this is a cheaper way to advertise than running commercials. It's all about trying to get people aware of Afrezza. Hopefully it will work. |
|
|
|
Post by mindovermatter on Nov 9, 2015 19:51:35 GMT -5
Thank you for replying Stevil. No one here dislikes you, or at least I don't. How can someone who holds 25K shares, get so down on the company? You stated that you're underwater on this. Why do you try to bring it down further then? You're in med school, yet put a substantial amount of cash into MNKD, now struggling as a result, but you still post neg on it? Makes no sense to me, but whatever. Aloha. Good to see you over here Denise. I have read your posts on Ihub for the last few months. Please let us know when you start using Afrezza and how it is working out for you. God knows MNKD can use all the new patients it can get now. |
|
